J eLabNext provides a One-Stop Solution for Deka Bioscience Case Study – November 2021Goal Science: Next-generation targeted cytokine therapy coupled with precision medicine patient selection. Based on years of research, we have developed first in class DiakinesTM, novel dual cytokine molecules, and disease specific assays for patients with cancer and inflammatory diseases. Business: having recently secured $20M in Series A funding, we plan to file an IND for our lead oncology molecule, cutting a path to scientific progress, therapeutic advances, and sustainable profitability through patterning/M&A. Deka Bioscience Deka Bioscience is a three-year-old biotechnology R&D startup focused on the discovery and development of the next generation of cytokine therapies to treat dev

Join for free to read